Antibodies to NTB-A

Details Antibodies to NTB-A Antibodies to NTB-A

2007-08-17

2010-12-07

Rawlings, Stephen L (Department: 1643)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Blood proteins or globulins, e.g., proteoglycans, platelet...

C530S350000, C530S387300, C530S388100, C435S326000, C435S328000

Reexamination Certificate

active

07847067

ABSTRACT:
Anti-NTB-A antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. Also described are methods of using such antibodies and antigen-binding regions to bind NTB-A and treat diseases, such as hematologic malignancies, which are characterized by expression of NTB-A.

REFERENCES:
patent: 7029677 (2006-04-01), Dedera et al.
patent: 7378253 (2008-05-01), Dedera et al.
patent: 2003/0099661 (2003-05-01), Valdez et al.
patent: 2004/0091478 (2004-05-01), Furusako et al.
Amlot et al, “A phase 1 study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy,” Blood, 82:2624-2633 (1993).
Bottino et al, “NTB-A, a novel SH2D1A-associated surface molecule contributing to the inability of natural killer cells to kill Epstein-Barr virus-infected B cells in X-linked hyperproliferative disease,” J. Exp. Med. 194:235-246 (2001).
Cao et al, “NTB-A receptor crystal structure: insights into homophilic interactions in the signaling lymphocytic activation molecule receptor family,” Immunity, 25:559-570 (2006).
De La Fuente, et al, “CD84 leukocyte antigen is a new member of the Ig superfamily,” Blood, 90:2398-2405 (1997).
Falco et al, “Homophilic interaction of NTBA, a member of the CD2 molecular family: induction of cytotoxicity and cytokine release in human NK cells,” Eur. J. Immunol., 34:1663-1672 (2004).
Green et al, “Monoclonal antibody therapy for solid tumors,” Cancer Treatment Reviews, 26:269-286 (2000).
Guckel et al, “Anti-CD2 antibodies induce T cell unresponsiveness in vivo,” J. Exp. Med., 174:957-967 (1991).
Malony et al, “The anti-tumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL) cell lines,” Blood, 88:637a (1996).
Malony et al, “IDEC C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma,” Blood, 90:2188-2195 (1997).
Press et al, “Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas,” Blood, 69:584-591 (1987).
Qin et al, “Anti-CD2 receptor and anti-CD2 ligand (CD48) antibodies synergize to prolong allograft survival,” J. Exp. Med., 179:341-346 (1994).
Stark and Watzl, “2B4 (CD244), NTB-A and CRACC (CS1) stimulate cytotoxicity but no proliferation in human NK cells,” Int. Immunol., 18:241-247 (2006).
Valdez et al, “NTB-A, a new activating receptor in T cells that regulates autoimmune disease,” J. Biol. Chem., 279:18662-18663 (2004).
Veillette, “Immune regulation by SLAM family receptors and SAP-related adaptors,” Nat. Rev. Immunol., 6:56-66 (2006).
Claus et al, “Regulation of NK cell activity by 2B4, NTB-A and CRACC,” Frontiers in Bioscience, 13:956-965 (2008).
Griewank et al, “Homotypic interactions mediated by Ly108 and SLAM control NKT lineage development,” Immunity, 27:751-762 (2007).
Korver et al, “The lymphoid cell surface receptor NTB-A: a novel monoclonal antibody target for leukaemia and lymphoma therapeutics,” Br. J. Haematol., 137:307-318 (2007).
Ma et al, “Regulation of cellular and humoral immune responses by the SLAM and SAP families of molecules,” Annu. Rev. Immunol., 25:337-379 (2007).
Tangye et al, “Functional requirements for interactions between CD84 and Src homology 2 domain-containing proteins and their contributions to human T cell activation,” J. Immunol., 171:2485-2495 (2003).
Velikovsky et al, “Structure of natural killer receptor 2B4 bound to CD48 reveals basis for heterophilic recognition in signaling lymphocyte activation molecule family,” Immunity, 27:572-584 (2007).
Yan et al, “Structure of CD84 provides insight into SLAM family function,” Proc. Natl. Acad. Sci. USA, 104:10583-10588 (2007).
Zhong et al, “Control of T lymphocyte signaling by Ly108, a SLAM family receptor implicated in auto-immunity,” JBC Papers in Press, published May 15, 2008 as Manuscript M800209200.

Affiliated with

Also associated with

Rating

Antibodies to NTB-A does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibodies to NTB-A, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies to NTB-A will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4158865